Trial in Progress: A Phase 2, Randomized, Open-Label Study of Trilaciclib with First-Line, Platinum-Based Chemotherapy and Avelumab Maintenance in Untreated Patients with Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3).